Učitavanje...
Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells
OBJECTIVES: Immunotherapy that targets the programmed death-1 / programmed death-ligand 1 (PD-L1) axis has been approved for treatment of non-small cell lung cancer (NSCLC) patients in many countries. However, our current understanding of the role of immunotherapies on NSCLC patients with epidermal...
Spremljeno u:
| Izdano u: | Lung Cancer |
|---|---|
| Glavni autori: | , , , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2017
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6174882/ https://ncbi.nlm.nih.gov/pubmed/28577937 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.lungcan.2017.04.010 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|